Document is current
Any future updates will be listed below
-
Authors
Ward, Henry N.
Aregger, Michael https://orcid.org/0000-0001-6443-9870
Gonatopoulos-Pournatzis, Thomas https://orcid.org/0000-0003-2669-2570
Billmann, Maximilian
Ohsumi, Toshiro K.
Brown, Kevin R.
Blencowe, Benjamin J.
Moffat, Jason https://orcid.org/0000-0002-5663-8586
Myers, Chad L. https://orcid.org/0000-0002-1026-5972
-
Funding
Funding for this research was provided by:
National Science Foundation (1818293, 1818293, 1818293)
U.S. Department of Health & Human Services | National Institutes of Health (R01HG005084, R01HG005853, R01HG005084, R01HG005853, R01HG005084, R01HG005853, T32GM008347)
U.S. Department of Health & Human Services | National Institutes of Health
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P300PA_164667)
Gouvernement du Canada | Canadian Institutes of Health Research (FDN-148434, MOP-142375)
Ontario Institute for Regenerative Medicine
Genome Canada (OGI-157)
- License Information
-
More Information
Article History
Received: 26 August 2020
Accepted: 3 June 2021
First Online: 10 September 2021
Competing interests
: A patent application (no. GB 1907733.8) describing the development and applications of CHyMErA, to the University of Toronto and T.G.-P., M.A., K.R.B., J.M. and B.J.B., is pending. J.M. previously performed sponsored research for Repare Therapeutics.
